AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis
AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update - Italian Association for the Study of the Liver (AISF) & Italian Association of Transfusion Medicine and Immunohematology (SIMTI)
Since the publication in 2016 of the recommendations on the appropriate use of albumin in patients with liver cirrhosis endorsed by the Italian Association for the Study of the Liver (AISF) and the Italian Association of Transfusion Medicine and Immunohematology (SIMTI)1,2, a considerable amount of pathophysiological and clinical data have been collected on the long-term administration of human albumin in decompensated cirrhosis. Considering the potential impact of these novel results on daily clinical practice, which will likely lead to an increase in the demand for human albumin, and taking into account the limited availability of this blood product, the two scientific associations nominated a panel of experts to review the available clinical literature and produce new practical clinical recommendations for the long-term use of human albumin in patients with decompensated cirrhosis.